Literature DB >> 12446366

Correlation between erythrocyte aldose reductase level and human diabetic retinopathy.

N Oishi1, E Kubo, Y Takamura, K Maekawa, T Tanimoto, Y Akagi.   

Abstract

AIM: To examine the relation between aldose reductase (AR) and the development and progression of diabetic retinopathy by comparing the erythrocyte AR levels with the prevalence of diabetic retinopathy in NIDDM patients.
METHODS: A clinic based cross sectional study was used. 611 NIDDM patients and 73 controls were enrolled. Erythrocyte AR levels were determined by ELISA. These AR levels were then correlated with patient age, duration of diabetes, and HbA(1c) levels. AR levels were also correlated with the prevalence of diabetic retinopathy in the entire NIDDM patient group and in three subgroups formed by separating the NIDDM patients by their duration of diabetes. The prevalence of diabetic retinopathy significantly increased with increased erythrocyte AR levels in patients with duration of diabetes of less than 10 years. A similar, but non-significant correlation between the prevalence of retinopathy and increased erythrocyte AR levels was observed in patients with diabetes duration of 10-20 and >/=20 years.
RESULTS: The prevalence of diabetic retinopathy increased with increased erythrocyte AR levels in NIDDM patients with a duration of diabetes of less than 10 years.
CONCLUSION: It was suggested that the inhibition of AR in patients with early NIDDM might be beneficial in reducing the development of diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12446366      PMCID: PMC1771419          DOI: 10.1136/bjo.86.12.1363

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  23 in total

1.  A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1990-09

2.  Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors.

Authors:  P F Kador; Y Akagi; Y Takahashi; H Ikebe; M Wyman; J H Kinoshita
Journal:  Arch Ophthalmol       Date:  1990-09

3.  Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors.

Authors:  P F Kador; Y Akagi; H Terubayashi; M Wyman; J H Kinoshita
Journal:  Arch Ophthalmol       Date:  1988-08

4.  Cataracts in galactosemia. The Jonas S. Friedenwald Memorial Lecture.

Authors:  J H Kinoshita
Journal:  Invest Ophthalmol       Date:  1965-10

5.  Localization of aldose reductase in the human eye.

Authors:  Y Akagi; Y Yajima; P F Kador; T Kuwabara; J H Kinoshita
Journal:  Diabetes       Date:  1984-06       Impact factor: 9.461

6.  A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes.

Authors:  Y L Kao; K Donaghue; A Chan; J Knight; M Silink
Journal:  Diabetes       Date:  1999-06       Impact factor: 9.461

7.  Diabeteslike preproliferative retinal changes in galactose-fed dogs.

Authors:  Y Takahashi; M Wyman; F Ferris; P F Kador
Journal:  Arch Ophthalmol       Date:  1992-09

8.  High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients.

Authors:  C Nishimura; T Saito; T Ito; Y Omori; T Tanimoto
Journal:  Diabetologia       Date:  1994-03       Impact factor: 10.122

9.  Aldose reductase localization in human retinal mural cells.

Authors:  Y Akagi; P F Kador; T Kuwabara; J H Kinoshita
Journal:  Invest Ophthalmol Vis Sci       Date:  1983-11       Impact factor: 4.799

10.  Aldose reductase inhibitor (CT-112) eyedrops for diabetic corneal epitheliopathy.

Authors:  Y Ohashi; M Matsuda; H Hosotani; Y Tano; I Ishimoto; M Fukuda; R Manabe
Journal:  Am J Ophthalmol       Date:  1988-03-15       Impact factor: 5.258

View more
  6 in total

Review 1.  Identifying Common Genetic Risk Factors of Diabetic Neuropathies.

Authors:  Ini-Isabée Witzel; Herbert F Jelinek; Kinda Khalaf; Sungmun Lee; Ahsan H Khandoker; Habiba Alsafar
Journal:  Front Endocrinol (Lausanne)       Date:  2015-05-28       Impact factor: 5.555

2.  Bioactivity Focus of α-Cyano-4-hydroxycinnamic acid (CHCA) Leads to Effective Multifunctional Aldose Reductase Inhibitors.

Authors:  Laitao Zhang; Yi-Fang Li; Sheng Yuan; Shijie Zhang; Huanhuan Zheng; Jie Liu; Pinghua Sun; Yijun Gu; Hiroshi Kurihara; Rong-Rong He; Heru Chen
Journal:  Sci Rep       Date:  2016-04-25       Impact factor: 4.379

3.  Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy.

Authors:  G Bhanuprakash Reddy; A Satyanarayana; N Balakrishna; Radha Ayyagari; M Padma; K Viswanath; J Mark Petrash
Journal:  Mol Vis       Date:  2008-03-24       Impact factor: 2.367

4.  A new gestational diabetes mellitus model: hyperglycemia-induced eye malformation via inhibition of Pax6 in the chick embryo.

Authors:  Shi-Jie Zhang; Yi-Fang Li; Rui-Rong Tan; Bun Tsoi; Wen-Shan Huang; Yi-Hua Huang; Xiao-Long Tang; Dan Hu; Nan Yao; Xuesong Yang; Hiroshi Kurihara; Qi Wang; Rong-Rong He
Journal:  Dis Model Mech       Date:  2016-01-07       Impact factor: 5.758

5.  Astaxanthin inhibits aldose reductase activity in Psammomys obesus, a model of type 2 diabetes and diabetic retinopathy.

Authors:  Maha Benlarbi-Ben Khedher; Khouloud Hajri; Ahmed Dellaa; Basma Baccouche; Imane Hammoum; Nourhene Boudhrioua-Mihoubi; Wissal Dhifi; Rafika Ben Chaouacha-Chekir
Journal:  Food Sci Nutr       Date:  2019-11-12       Impact factor: 2.863

6.  The chlorite-based drug WF10 constantly reduces hemoglobin A1c values and improves glucose control in diabetes patients with severe foot syndrome.

Authors:  Paiboon Maraprygsavan; Jarasporn Mongkolsuk; Juergen Arnhold; Friedrich-Wilhelm Kuehne
Journal:  J Clin Transl Endocrinol       Date:  2016-05-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.